30 closest matches · ranked by relevance
Healthcare Associated Pneumonia
Primary: Pathogens of Healthcare Associated Pneumonia, Measured by the Number of Participants — 15; 51; 195; 269 Participants
Pneumonia, Bacterial
Primary: Number of Participants Surviving Through LFU Visit — 191; 196; 64; 57 Participants — p=0.4263
Bacterial Pneumonia
Primary: Percentage of Participants With All-cause Mortality (ACM) Through Day 28 in the Modified Intention-to-treat (MITT) Population — 15.9; 21.3 Percentage of participants…
Pneumonia · Bacterial Pneumonia · Ventilator-Associated Pneumonia
Primary: Clinical Response Rates and 95% Confidence Intervals at the Test-of-Cure Assessment. — 63.9; 66.0; 64.4; 50.0 Percentage of participants
Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
Primary: Day 14 All-cause Mortality Rate — 3.0; 2.7 percentage of participants
Nosocomial Pneumonia (NP) · Ventilator-associated Pneumonia (VAP)
Primary: The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Clinically Modified Intent-to-treat Analysis Set (Co-primary Analyses) — 245; 270; 79; 70…
Healthcare-Associated Pneumonia · Ventilator-Associated Pneumonia · Lung Diseases
Primary: Percentage of Participants With All Cause Mortality in the Intent-to-Treat (ITT) Population - Day 28 — 24.0; 25.3 Percentage of Participants
Pseudomonas Aeruginosa
Primary: Percentage of Participants With Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa — 18.1; 12.5; 22.4 Percentage of participants — p=0.491
Pneumonia
Primary: Hospital Acquired Pneumonia Occurrences — 2; 13 participants
Hospital-Acquired Bacterial Pneumonia · Ventilator-Associated Bacterial Pneumonia
Primary: Percentage of Participants With All-cause Mortality Through Day 28 in the Modified Intent to Treat (MITT) Population — 11.2; 5.9 Percentage of Participants — p=0.024
Pneumonia
Primary: Length of Hospital Stay — 7.3; 5.8 Days
Community-acquired Pneumonia (CAP) · Hospital-acquired Pneumonia (HAP)
Primary: Adverse Events — 10; 5; 1; 0 Participants
Bacterial Pneumonia
Primary: Clinical Response — 227; 228; 53; 52 participants
Pneumonia
Primary: Use of Antibiotics in Each Group — 28; 52 participants
Bacterial Pneumonia
Primary: Clinical Response — 214; 221; 46; 68 participants
VAP - Ventilator Associated Pneumonia
Primary: Total Number of Deaths in the Pre vs Post-intervention Time Periods Among Study Participants Per 1000 Mechanically Ventilated Patient Days — 72; 73 Deaths per 1000…
Acinetobacter Baumannii-calcoaceticus Complex · Hospital-acquired Bacterial Pneumonia · Ventilator-associated Bacterial Pneumonia
Primary: Proportion of Patients With All-Cause Mortality in CRABC m-MITT Population — 12; 20 Participants
Pseudomonas Aeruginosa Pneumonia
Primary: Clinical Cure on Day 21 — 34; 37; 6; 5 Participants — p=0.6154
Pneumonia
Primary: Extended-Spectrum Days Of Antibacterial Therapy (ES-DOT) Per Empiric Day — 38690; 27971 Extended-Spectrum Days-of-Therapy
Healthcare-associated Pneumonia (HCAP) · Hospital Acquired Pneumonia (HAP) · Ventilator Associated Pneumonia (VAP)
Primary: All-cause Mortality Rate at Day 14 — 12.4; 11.6 percentage of participants — p=0.0020
Ventilator-Associated Pneumonia
Primary: Change in Antibiotic Usage or Exposure — 11.87; 7.76 days — p=0.26
Community Acquired Pneumonia
Primary: Use of Antibiotics in Each Group — 9; 21 participants — p=0.01
Osteomyelitis
Primary: Description of the Clinical and Epidemiological Profile of Patients With Infection — 92; 26; 25; 21 Participants
Pneumonia
Primary: Time to 30-day Mortality — 15; 14 days
Infections, Hospital · Ventilator-Associated Pneumonia · Mechanical Ventilation Complication
Primary: Development of VAP (Clinical Pulmonary Infection Score) — 4.13; 4.45 units on a scale — p=0.1763
Pneumonia
Primary: Number of Participants With All-Cause Mortality in the Intent-to-Treat (ITT) Population — 103; 95 Participants
Sepsis · Procalcitonin · Antimicrobial Stewardship
Primary: Days of Antibiotic Therapy in the First 14 Days Following Randomization — 7.6; 6.6 days
Methicillin-Resistant Staphylococcus Aureus (MRSA) · Hospital-Acquired Pneumonia
Primary: Percentage of Participants With Clinical Success — 85; 69 percentage of participants — p=0.009
Hospital-Acquired Pneumonia
Primary: Percentage of Participants With Clinical Cure at Test of Cure (TOC) Visit: Clinical Modified Intent-to-Treat (cMITT) Population — 62.7 Percentage of participants
Community-Acquired Bacterial Pneumonia · Lung Infection of Individual Not Recently Hospitalized
Primary: Clinical Cure Rate for Ceftaroline Compared to That for Ceftriaxone at Test of Cure (TOC) in CE Population — 217; 178; 41; 62 Participants